Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan-McDermid Syndrome in Children and Adolescents
Your question will be sent privately to Neuren Pharmaceuticals. The company may choose to make this question public.
Start the conversation
Ask Neuren Pharmaceuticals a question about this update.
